Based on the Piramal Pharma Limited stock forecast from 2 analysts, the average analyst target price for Piramal Pharma Limited is INR 130.00 over the next 12 months. Piramal Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Piramal Pharma Limited is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Piramal Pharma Limited’s stock price was INR 139.45. Piramal Pharma Limited’s stock price has changed by +0.50% over the past week, +15.87% over the past month and +79.82% over the last year.
No recent analyst target price found for Piramal Pharma Limited
No recent average analyst rating found for Piramal Pharma Limited
Company Overview Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited. Read Less
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates ...Read More
Frequently Asked Questions About Piramal Pharma Limited (PPLPHARMA:NSE) Stock
Based on ratings from 2 analysts Piramal Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PPLPHARMA:NSE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for PPLPHARMA:NSE is INR 130.00 over the next 12 months. The maximum analyst target price is INR 130 while the minimum anlayst target price is INR 130.
PPLPHARMA:NSE stock's Price/Earning ratio is 53.82.
Our analysis grades PPLPHARMA:NSE stock's Price / Earning ratio at F. This means that PPLPHARMA:NSE stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this PPLPHARMA:NSE may be a overvalued for its sector.
The last closing price of PPLPHARMA:NSE's stock was INR 139.45.
The most recent market capitalization for PPLPHARMA:NSE is INR 184.97B.
Based on targets from 2 analysts, the average taret price for PPLPHARMA:NSE is projected at INR 130.00 over the next 12 months.
This means that PPLPHARMA:NSE's stock price may go down by -6.78% over the next 12 months.
We can't find any ETFs which contains Piramal Pharma Limited's stock.
As per our most recent records Piramal Pharma Limited has 6,295 Employees.
Piramal Pharma Limited's registered address is Piramal Ananta, Mumbai, India, 400 070.
You can get more information about it from Piramal Pharma Limited's website at https://www.piramal.com/businesses/piramal-pharma/.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPLPHARMA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
